IFOSFAMIDE ENANTIOMERS - PHARMACOKINETICS IN CHILDREN

被引:18
作者
PRASAD, VK
CORLETT, SA
ABAASI, K
HENEY, D
LEWIS, I
CHRYSTYN, H
机构
[1] UNIV BRADFORD,SCH PHARM,BRADFORD BD7 1DP,W YORKSHIRE,ENGLAND
[2] ST JAMESS UNIV HOSP,YORKSHIRE PAEDIAT ONCOL UNIT,LEEDS LS9 7TF,ENGLAND
关键词
IFOSFAMIDE; ENANTIOMERS; CHILDREN;
D O I
10.1007/s002800050170
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ifosfamide, like other oxazaphosphorine drugs, is chiral and there is some evidence, mainly from animal studies, of stereo-selective differences in metabolism, excretion and cytotoxic activity between the two enantiomers. The pharmacokinetics of racemic ifosfamide (RAC-IFO), R-ifosfamide (R-IFO) and S-ifosfamide (S-IFO) were studied in five children who received intravenous therapy with racemic ifosfamide on 3 consecutive days. The clearance of S-IFO was greater than that of R-IFO. The clearance value at the end of the infusion was faster than the respective rate measured at the beginning of or during the ifosfamide regimens in four children and, therefore, suggests autoinduction of elimination of both enantiomers.
引用
收藏
页码:447 / 449
页数:3
相关论文
共 10 条
[1]  
BLASCHKE G, 1986, ARZNEIMITTEL-FORSCH, V36-2, P1493
[2]   URINARY-EXCRETION OF THE ENANTIOMERS OF IFOSFAMIDE AND ITS INACTIVE METABOLITES IN CHILDREN [J].
BOOS, J ;
WELSLAU, U ;
RITTER, J ;
BLASCHKE, G ;
SCHELLONG, G .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (06) :455-460
[3]   ENANTIOMERIC SEPARATION OF R-IFOSFAMIDE AND S-IFOSFAMIDE AND THEIR DETERMINATION IN SERUM FROM CLINICAL SUBJECTS [J].
CORLETT, SA ;
CHRYSTYN, H .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1994, 654 (01) :152-158
[4]  
CROM WR, 1991, CLIN PHARMACOL THER, V49, P195
[5]   ENANTIOMERS OF CYCLOPHOSPHAMIDE AND IPHOSPHAMIDE [J].
FARMER, PB .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (01) :145-148
[6]  
KUSNIERCZYK H, 1986, J IMMUNOPHARMACOL, V8, P455
[7]   FRACTIONATED IFOSFAMIDE THERAPY PRODUCES A TIME-DEPENDENT INCREASE IN IFOSFAMIDE METABOLISM [J].
LEWIS, LD ;
FITZGERALD, DL ;
HARPER, PG ;
ROGERS, HJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (05) :725-732
[8]  
MASUREL D, 1990, CANCER RES, V50, P252
[9]  
NELSON RL, 1976, CLIN PHARMACOL THER, V19, P365
[10]  
WAINER IW, 1988, P AN M AM SOC CLIN, V7, P72